PAI
VKTX icon

Pittenger & Anderson Inc’s Viking Therapeutics VKTX Stock Holding History

Pittenger & Anderson Inc’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,400
Closed -$96.6K – 457
2024
Q4 		$96.6K Sell
2,400
-240
-9% -$13.7K ﹤0.01% 267
2024
Q3 		$167K Hold
2,640
– – 0.01% 240
2024
Q2 		$140K Hold
2,640
– – 0.01% 244
2024
Q1 		$216K Buy
+2,640
New +$117K 0.01% 224

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pittenger & Anderson Inc's VKTX Position: Q1 2025 in Review

Pittenger & Anderson Inc sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 2,400 shares — an estimated $96.6K sold.

Pittenger & Anderson Inc first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $216K in Q1 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Pittenger & Anderson Inc reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Pittenger & Anderson Inc sold 2,400 Viking Therapeutics shares in Q1 2025, an estimated $96.6K.
  • Pittenger & Anderson Inc first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Pittenger & Anderson Inc's Viking Therapeutics position peaked at $216K in Q1 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Pittenger & Anderson Inc's 13F filing for Q1 2025, filed 1 May 2025.